GLP-1 Protects Your Heart—Even When the Scale Moves Slowly

Learn how GLP-1 (like Semaglutide) may help lower heart risk for people living with overweight or obesity. GLĒO Wellness offers a compassionate weight loss program and weight reduction plan in Massachusetts and Colorado.

Good News for Your Heart

If you are living with overweight or obesity and have heart disease, there is hope. A large study called the SELECT Trial found that GLP-1 medicine (Semaglutide) lowered the risk of heart attack, stroke, or death from heart disease. This benefit showed up even when people did not see big weight changes at first. Your heart can gain protection while you follow a simple, sustainable weight loss plan.

At GLĒO Wellness, we see you as a whole person. Your weight loss program supports your health, comfort, and goals—without judgment.

What Did the Study Show?

• Who was in the study: Over 17,000 adults with a BMI of 27 or higher and heart disease. No one had diabetes.

• What they took: Semaglutide (a GLP-1) once each week, or placebo.

• What happened: People on Semaglutide had fewer major heart events.

• A key finding: Early weight loss did not predict who got heart protection. A smaller waist size (less belly/visceral fat) was linked to lower risk, explaining about one-third of the benefit. The rest likely comes from other helpful effects—like less inflammation and better blood pressure and cholesterol.

What this means: Your heart may be protected even if the scale moves slowly. A compassionate weight reduction program can still help you feel better and protect your health.

Why Your Waist Matters

Belly fat around your organs can raise inflammation and blood pressure. In the study, people who reduced waist size had fewer heart events. At GLĒO, we look at more than weight. We track body composition, waist measurements, blood pressure, cholesterol, sleep, energy, and how you feel. Your weight reduction plan is about more than the number on the scale—it’s about protecting your heart and building daily habits that last.

How GLĒO Builds a Heart-Smart Plan

We support adults in Massachusetts and Colorado with a simple, supportive approach:

• GLP-1 (Semaglutide) guidance: We check if it’s right for you, help with dosing, and support side effects—within a full weight loss program.

• Protect your muscle: We use a protein-forward eating plan and strength training so your weight loss plan keeps you strong.

• Track what matters: Waist size, body composition, blood pressure, cholesterol, sleep, energy, and labs—not only weight.

• Real-life support: Sleep, stress, movement, and simple meals are part of your weight reduction program so changes fit your life.

Looking for a weight reduction program that feels kind and doable? We’ll help you create a plan that works at home, at work, and with your schedule.

Try These Simple Steps This Week

Pick one or two to add to your weight loss plan:

• Protein at each meal (eggs, Greek yogurt, chicken, tofu, beans).

• Strength training 2–3 days a week (bodyweight or light weights).

• Turn off screens 1 hour before bed for better sleep and fewer cravings.

• Drink water through the day and add fiber (veggies, beans, berries).

Small steps add up. These can support a smaller waist and better heart health—especially when paired with a GLP-1 weight reduction plan.

Compassionate Weight Care in Massachusetts and Colorado

Many people search for a “medical weight loss program” At GLĒO, we offer compassionate, stigma-free care with GLP-1 (when appropriate) and lifestyle medicine. Your weight loss program and weight reduction plan are built for you—simple, safe, and science-based.

• Learn more about our approach: GLĒO's Weight Care Program

• Ready to talk with us? Book your FREE consultation now

Study reference

This blog is based on a prespecified analysis from the SELECT trial, a large study of semaglutide in people living with overweight or obesity and heart disease (without diabetes): Deanfield J, Lincoff AM, Kahn SE, et al. “Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial.” Published Oct 22, 2025, in The Lancet (Open Access). You can read the article here: The Lancet – SELECT prespecified analysis.

DISCLAIMER

The content provided on this blog is for informational purposes only and is not intended to offer medical advice. It does not establish nor imply a clinician-patient relationship. Please always seek the advice of your healthcare provider regarding any medical concerns or treatments.